| 前收市價 | 27.75 |
| 開市 | 27.80 |
| 買盤 | 27.11 x 300 |
| 賣出價 | 27.19 x 300 |
| 今日波幅 | 26.97 - 27.97 |
| 52 週波幅 | 16.58 - 45.58 |
| 成交量 | |
| 平均成交量 | 1,166,628 |
| 市值 | 3.948B |
| Beta 值 (5 年，每月) | 0.70 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -1.81 |
| 業績公佈日 | 2024年5月13日 - 2024年5月27日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 50.86 |
Insider MonkeyShould You Hold Immunovant (IMVT)?
Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here. The fund advanced 8.92% (Institutional Shares) in the quarter compared to an 8.52% gain for the Russell 3000 Health Care Index (benchmark) and a 10.56% increase for the S&P […]
ZacksHere's Why You Should Add Immunovant (IMVT) to Your Portfolio
Immunovant's (IMVT) late-stage studies evaluating its lead candidate, batoclimab, for various autoimmune indications are progressing well. Several data readouts are expected in 2024 and 2025.
ZacksWhat Makes Immunovant (IMVT) a New Buy Stock
Immunovant (IMVT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
